Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Kazuhiko Ogawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8872-7690; OpenAlex author ID A5101750702. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers

Papers 12

  1. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Co-author DOI 10.1111/cas.16152↗
  2. Revealing neuropilin expression patterns in pancreatic cancer: From single‑cell to therapeutic opportunities (Review). Co-author DOI 10.3892/ol.2024.14247↗
  3. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes. Co-author DOI 10.1038/s41598-023-41835-6↗
  4. Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15204917↗
  5. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.104659↗
  6. N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. Last author DOI 10.1038/s41598-022-15196-5↗
  7. Emerging roles of long noncoding and circular RNAs in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fphys.2022.1025923↗
  8. Improvement of image quality for pancreatic cancer using deep learning-generated virtual monochromatic images: Comparison with single-energy computed tomograph… Co-author DOI 10.1016/j.ejmp.2021.03.035↗
  9. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Last author DOI 10.3892/ijo.2017.4219↗
  10. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Co-author DOI 10.1016/j.radonc.2015.01.004↗
  11. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Co-author DOI 10.1093/jjco/hyu224↗
  12. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival. Co-author DOI 10.1016/j.ijrobp.2011.07.013↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hideshi Ishii · 6 shared papers, 2018–2024 · strength 0.83
  2. Shotaro Tatekawa · 5 shared papers, 2022–2024 · strength 0.76
  3. Yuichiro Doki · 6 shared papers, 2015–2024 · strength 0.68
  4. Hidetoshi Eguchi · 5 shared papers, 2015–2024 · strength 0.60
  5. Tomoaki Hara · 3 shared papers, 2022–2024 · strength 0.51
  6. Hiromichi Sato · 3 shared papers, 2022–2024 · strength 0.51
  7. Kazuki Sasaki · 3 shared papers, 2022–2024 · strength 0.42
  8. Melissa L. Fishel · 2 shared papers, 2023 · strength 0.36
  9. Qingji Huo · 2 shared papers, 2023 · strength 0.36
  10. Kexin Li · 2 shared papers, 2023 · strength 0.36
  11. Hiroki Yokota · 2 shared papers, 2023 · strength 0.36
  12. Yoshiko Tsuji · 2 shared papers, 2024 · strength 0.36
  13. Sikun Meng · 2 shared papers, 2024 · strength 0.36
  14. Hidenori Takahashi · 3 shared papers, 2015–2024 · strength 0.32
  15. Yu Takeda · 2 shared papers, 2022–2024 · strength 0.27
  16. Daisaku Yamada · 2 shared papers, 2022–2024 · strength 0.27
  17. Ryota Chijimatsu · 2 shared papers, 2022 · strength 0.25
  18. Teruki Teshima · 2 shared papers, 2015–2021 · strength 0.17
  19. Yoshito Tomimaru · 2 shared papers, 2015–2022 · strength 0.16
  20. Suguru Mitsufuji · 1 shared paper, 2022 · strength 0.14
  21. Hirofumi Akita · 1 shared paper, 2022 · strength 0.14
  22. Yoshiki Murakumo · 1 shared paper, 2022 · strength 0.14
  23. Shingo Ohira · 1 shared paper, 2021 · strength 0.12
  24. Masahiko Koizumi · 1 shared paper, 2021 · strength 0.12
  25. Kosuke Taketo · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.